DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
post-insult time to onset of experimental autoimmune encephalomyelitis |
myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
male |
65 days-112 days |
21 |
21.9 |
d |
2.47 |
11.3 |
in vivo visual assessment |
0.0 |
0 |
|
69494 |
837 |
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
male |
65 days-112 days |
21 |
11.7 |
d |
2.23 |
10.2 |
in vivo visual assessment |
0.0 |
0 |
|
69490 |
837 |
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
body weight |
control condition |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
body mass |
female |
56 days-77 days |
0 |
153.5 |
g |
|
16.7 |
body weighing method |
0.0 |
0 |
|
68121 |
837 |
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
percentage of study population developing experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
female |
91 days-112 days |
13 |
69.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
|
68123 |
837 |
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
percentage of study population developing experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
male |
91 days-112 days |
21 |
76.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
visual observation |
69488 |
837 |
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
female |
65 days-112 days |
0 |
10.1 |
d |
|
9.5 |
in vivo visual assessment |
0.0 |
0 |
|
69502 |
837 |
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
post-insult time to onset of experimental autoimmune encephalomyelitis |
myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
female |
65 days-112 days |
13 |
22.5 |
d |
3.58 |
12.9 |
in vivo visual assessment |
0.0 |
0 |
|
69492 |
837 |
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
percentage of study population developing experimental autoimmune encephalomyelitis during a period of time |
myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
female |
91 days-112 days |
0 |
69.0 |
% |
|
48.0 |
in vivo visual assessment |
0.0 |
0 |
visual observation |
69498 |
837 |
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
post-insult time to onset of experimental autoimmune encephalomyelitis |
myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
female |
65 days-112 days |
0 |
22.5 |
d |
|
12.9 |
in vivo visual assessment |
0.0 |
0 |
|
69500 |
837 |
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
female |
65 days-112 days |
13 |
10.1 |
d |
2.63 |
9.5 |
in vivo visual assessment |
0.0 |
0 |
|
69377 |
837 |